Jentadueto | ASweetLife

Jentadueto Approved in Europe for Treatment of Adults with Type 2 Diabetes

The European Commission has given Marketing Authorization to Jentadueto (linagliptin/metformin hydrochloride) tablets,Boehringer Ingelheim and Eli Lilly's medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta tablets, marketed under the trade name Trajenta in Europe) and metformin in a single tablet taken twice daily.

Jentadueto, a Combination Therapy for Type 2 Diabetes Recommended for approval in the EU

The European Medicines Agency's (EMA) medicinal committee has recommended the approval of Jentadueto, a type 2 diabetes drug, from Boehringer Ingelheim and Eli Lilly. Jentadueto (linagliptin/metformin hydrochloride) tablets are a medicine combining the DPP-4 inhibitor, linagliptin...

Jentadueto, Lilly’s New Type 2 Diabetes Drug is Now Available in the US

Eli Lilly and Boehringer Ingelheim have announced Jentadueto tablets are now available by prescription in pharmacies across the U.S. Jentadueto is a new prescription medication for type 2 diabetes patients who need to control their blood sugar. Jentadueto is a twice...

FDA Approves New Type 2 Diabetes Combination Medication Jentadueto

The FDA has approved Eli Lilly and Boehringer Ingelheim's new type 2 diabetes treatment Jentadueto (linagliptin/metformin hydrochloride), which combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet...

Tag: Jentadueto